Page 238 - Read Online

Page 8 of 8 Niu et al. Neuroimmunol Neuroinflammation 2018;5:32 I http://dx.doi.org/10.20517/2347-8659.2018.39

Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med
2018;378:2093-104.
29. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M,
Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR,
Jr., Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous
non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
30. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse
D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C,
Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med
2015;373:123-35.
31. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G,
Jr., Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.
32. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL,
Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS,
Sandler A, Gandara DR. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65.
33. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F,
Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A. Atezolizumab versus docetaxel for patients with previously treated
non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46.
34. Berghoff AS, Venur VA, Preusser M, Ahluwalia MS. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am
Soc Clin Oncol Educ Book 2016;35:e116-22.
35. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev
Cancer 2012;12:298-306.
36. Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, Birner P, Bartsch R, Preusser M. Tumor infiltrating lympho-
cytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J Neurooncol 2016;130:19-29.
37. Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H,
Zielinski C, Bartsch R, Birner P, Galon J, Preusser M. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema
and overall survival time in patients with brain metastases. Oncoimmunology 2016;5:e1057388.
38. Reck M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Immunotherapy 2018;10:93-105.
39. Crinò L, Bidoli P, Ulivi P, Minenza E, Cortesi E, Garassino M, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G,
Samaritani R, Ciuffreda L, Frassoldati A, Bregni MB, Santo A, Piantedosi F, Illiano A, De Marinis F, Delmonte A. Italian Nivolumab
Expanded Access Programme (EAP): data from patients with advanced non-squamous NSCLC and brain metastases. J Thoracic Oncol
2017;12:S1915.
40. Gauvain C, Vauleon E, Chouaid C, Lerhun E, Jabot L, Scherpereel A, Vinas F, Cortot AB, Monnet I. Intracerebral efficacy and tolerance
of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer 2018;116:62-6.
41. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde
U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with
melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Lancet Oncol 2016;17:976-83.
42. Goldberg SB, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W,
Chiang V, Kluger HM. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC)
treated with pembrolizumab. J Clin Oncol 2018;36 suppl:abstr2009.
43. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J,
Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Lancet Oncol 2012;13:459-65.
44. Tawbi H, Forsyth P, Algazi A, Hamid O, Hodi FS, Moschos S, Khushalani N, Gonzalez R, Lao C, Postow M, Atkins MB, Ernstoff M,
Puzanov I, Kudchadkar R, Thomas R, Tarhini A, Jiang J, Avila A, Demelo S, Margolin K. Efficacy and safety of nivolumab (NIVO)
plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J Clin
Oncol 2017;35 suppl:abstr9507.
45. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM,
McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised
phase 2 study. Lancet Oncol 2018;19:672-81.
46. Maurice C, Schneider R, Kiehl TR, Bavi P, Roehrl MH, Mason WP, Hogg D. Subacute CNS Demyelination after treatment with
nivolumab for melanoma. Cancer Immunol Res 2015;3:1299-302.